Amy Tseng is TissueTech’s President and Chief Executive Officer and a member of the company’s Board of Directors. Amy co-founded Bio-Tissue in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building Bio-Tissue into the industry leader in this sector and spearheading the founding of Amniox Medical to expand the Company’s technology into other healthcare sectors. She has guided the company through impressive levels of annual growth. Prior to founding Bio-Tissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy holds a Master of Business Administration from the University of Southern California.
Dr. Scheffer C. G. Tseng co-founded TissueTech and Bio-Tissue and is currently Chief Technology Officer for TissueTech and Chairman of the company’s Board of Directors. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a widely published physician scientist with more than 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications. Dr. Tseng holds a medical degree from National Taiwan University and a Doctorate in Experimental Pathology from the University of California. He completed his residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins, and his fellowship in cornea and external diseases at Massachusetts Eye and Ear Infirmary. Prior to co-founding TissueTech, Dr. Tseng was a Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine.
Devin Buckley joined TissueTech in 2013 with more than 12 years of experience in the life sciences industry. Prior to this, Devin was the Senior Vice President and General Counsel at Stiefel Laboratories, Inc., where he helped build what became the world’s largest dermatology company. Devin previously held positions with United Technologies, United Technologies/Pratt & Whitney, Day, Berry & Howard and Our Kids of Miami-Dade. Devin holds a Bachelor’s Degree from Yale University and a Juris Doctor from Georgetown University.
Michael Cornelius joined TissueTech as Chief Financial Officer in 2014 with more than 25 years of experience in public accounting and public and private corporations. Mr. Cornelius was previously with Stiefel Laboratories, serving as its Chief Financial Officer. Stiefel Laboratories was the largest privately-held dermatology company in the world, before it was acquired by GlaxoSmithKline in 2009. Mike began his career with the international accounting and consulting firm, Grant Thornton, where he specialized in US and International tax planning and also held senior level finance positions with IVAX Corporation and Sunglass Hut International. Mike holds a Bachelor of Science in Business Administration from Indiana University of Pennsylvania and is a Certified Public Accountant.
Adrian Roji joined the TissueTech executive team in January 2018. He has a diverse background managing multifaceted businesses, and is an expert on strategic marketing, sales, health economics and driving innovation through the partnership of research and development, operations and business development. Adrian’s career includes responsibility for the international strategic marketing of Allergan Corporation’s regenerative medicine, plastics surgery and body contouring business – a continuation of his leadership of that endeavor at LifeCell Corporation before acquisition by Allergan. Prior to that he was at Johnson & Johnson for 20 years with both global and US commercial responsibilities within its family of companies, including US Women’s Health and Urology, Vistakon, Ethicon, Ethicon-Endosurgery and Cordis among others.
Alan Petro joined the executive team in 2015 to lead TissueTech’s procurement, supply chain, manufacturing, distribution, and facilities operations. He has 30 years of experience leading product development, manufacturing, quality management and regulatory affairs for medical device, pharmaceutical, and biotechnology companies. During this time, he has held executive level positions with several market- leading companies including Siemens Healthcare, Carl Zeiss, Meditec and Acuson, as well as successfully positioning several start-up companies for acquisition. Alan holds a Bachelor of Science in Materials and Metallurgical Engineering from the University of Michigan, a Master of Business Administration from Marylhurst University, and a Master of Jurisprudence in Healthcare Law from Loyola University of Chicago.
Dr. Frank Young is a previous Commissioner of the U.S. Food and Drug Administration (FDA), and served as Deputy Assistant Secretary of the U.S. Department of Health and Human Services. He was previously Executive Vice President of Regulatory and Clinical Affairs at Braeburn Pharmaceuticals, Interim Vice President for Clinical and Regulatory Affairs of Bioventus Global, and has served in a leadership capacity with multiple other life sciences groups. Previous to his appointment to lead the FDA, Dr. Young was Dean of the School of Medicine and Dentistry at the University of Rochester. While serving at the U.S. Department of Health Human Services, Dr. Young received the Surgeon General’s Award for Outstanding Integrity, and the Surgeon General’s Exemplary Service Medal from the U.S. Public Health Service. In 2015, he received the Distinguished Scientist Award from the American College of Toxicology. Dr. Young has contributed to more than 200 scientific publications in biotechnology and pathology.